575 related articles for article (PubMed ID: 18056045)
21. Biochemical and molecular mechanisms of action of bisphosphonates.
Rogers MJ; Crockett JC; Coxon FP; Mönkkönen J
Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
[TBL] [Abstract][Full Text] [Related]
22. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.
Räikkönen J; Taskinen M; Dunford JE; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Biophys Res Commun; 2011 Apr; 407(4):663-7. PubMed ID: 21420384
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.
Rondeau JM; Bitsch F; Bourgier E; Geiser M; Hemmig R; Kroemer M; Lehmann S; Ramage P; Rieffel S; Strauss A; Green JR; Jahnke W
ChemMedChem; 2006 Feb; 1(2):267-73. PubMed ID: 16892359
[TBL] [Abstract][Full Text] [Related]
24. [Bisphosphonates in the treatment of multiple myeloma].
Stajszczyk M
Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
[TBL] [Abstract][Full Text] [Related]
25. [Development of bisphosphonates].
Nakatsuka K
Nihon Rinsho; 2003 Feb; 61(2):219-25. PubMed ID: 12638211
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon FP; Thompson K; Rogers MJ
Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of action of bisphosphonates.
Rodan GA
Annu Rev Pharmacol Toxicol; 1998; 38():375-88. PubMed ID: 9597160
[TBL] [Abstract][Full Text] [Related]
28. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
Plotkin LI; Manolagas SC; Bellido T
Bone; 2006 Sep; 39(3):443-52. PubMed ID: 16627025
[TBL] [Abstract][Full Text] [Related]
29. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Shakespeare WC; Metcalf CA; Wang Y; Sundaramoorthi R; Keenan T; Weigele M; Bohacek RS; Dalgarno DC; Sawyer TK
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):729-41. PubMed ID: 14579523
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Dunford JE; Kwaasi AA; Rogers MJ; Barnett BL; Ebetino FH; Russell RG; Oppermann U; Kavanagh KL
J Med Chem; 2008 Apr; 51(7):2187-95. PubMed ID: 18327899
[TBL] [Abstract][Full Text] [Related]
31. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates and primary hyperparathyroidism.
Rodan GA
J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis I; Kousidou OCh; Karamanos NK
In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
[TBL] [Abstract][Full Text] [Related]
34. [The use of bisphosphonates for treating pathological states in orthopedics].
Białecki P; Bohatyrewicz A; Machoy-Mokrzyńska A; Białecka M
Chir Narzadow Ruchu Ortop Pol; 2008; 73(4):266-73. PubMed ID: 18847019
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum.
Rogers MJ; Watts DJ; Russell RG; Ji X; Xiong X; Blackburn GM; Bayless AV; Ebetino FH
J Bone Miner Res; 1994 Jul; 9(7):1029-39. PubMed ID: 7942149
[TBL] [Abstract][Full Text] [Related]
36. New role for an established drug? Bisphosphonates as potential anticancer agents.
Koul HK; Koul S; Meacham RB
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):111-9. PubMed ID: 21876554
[TBL] [Abstract][Full Text] [Related]
37. Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures.
Nicolin V; Bareggi R; Baldini G; Bortul R; Martinelli B; Narducci P
Acta Histochem; 2007; 109(5):397-402. PubMed ID: 17574655
[TBL] [Abstract][Full Text] [Related]
38. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
van Beek ER; Cohen LH; Leroy IM; Ebetino FH; Löwik CW; Papapoulos SE
Bone; 2003 Nov; 33(5):805-11. PubMed ID: 14623056
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates and connexin 43: a critical review of evidence.
Sadr-Eshkevari P; Ashnagar S; Rashad A; Dietz M; Jackowski J; Abdulazim A; Prochnow N
Cell Commun Adhes; 2014 Oct; 21(5):241-7. PubMed ID: 24946183
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates: how do they work?
Papapoulos SE
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]